Unipolar depression\u2014comprising major depressive disorder (MDD), minor depression, and dysthymia\u2014is a highly prevalent psychiatric disorder affecting nearly 81 million individuals in the seven major markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Throughout our 2015-2025 study period, the unipolar depression therapy market will consist almost entirely of generic products that dominate treatment, particularly in the early lines. Only a few branded products\u2014namely, Allergan\u2019s vilazodone (Viibryd), Lundbeck\/Takeda Pharmaceutical\u2019s vortioxetine (Brintellix\/Trintellix), Allergan\/Pierre Fabre\u2019s levomilnacipran (Fetzima), Otsuka Pharmaceutical\/Lundbeck\u2019s brexpiprazole, Allergan\/Gedeon Richter\/Mitsubishi Tanabe Pharma\u2019s cariprazine (Vraylar), and Sumitomo Dainippon\/Sunovion\/Takeda Pharmaceutical\u2019s lurasidone (Latuda)\u2014will be competing for market share during the forecast period in this highly genericized space. Because of generic competition from current therapies, it is unlikely that any emerging drugs (, Janssen\u2019s esketamine, Alkermes\u2019s ALKS-5461, and Allergan\u2019s rapastinel) will become dominating first-line treatments; however, low patient response rates and even lower remission rates following treatment with first-line therapies leave opportunity for adjunctive agents for MDD and for monotherapies targeting specific patient subpopulations, particularly those with treatment-resistant depression (TRD) or residual symptoms of depression.
\nQuestions Answered:<\/p>\n
The unipolar depression market will decline in the first years of our forecast period (2015-2016). What is causing this market decline? Will any new drugs enter the market during this time, and if so, what will be their place in the treatment armamentarium?
\nStarting in 2017, the depression market will begin to experience a slow but steady upswing, owing in large part to increasing uptake of some of the newly marketed depression therapies. Which new therapies will experience the most robust growth, and why? How do interviewed experts expect to incorporate these newer therapies into the depression treatment algorithm in the face of strong generic competition from many well-entrenched products?
\nIn 2022, the depression market will have reached approximately $ billion (from a low of $ billion in 2016). Which drugs will be the market leaders in 2022? To what extent will patient share have shifted to newer agents from the older, inexpensive generic antidepressants, and what factors underlie this shift? Will there be any major changes in how depression is treated? Will any novel approaches to treating depression have reached the market?
\nNear the end of our forecast period (2022-2024), the depression market will again be in decline before it experiences a resurgence in sales in our final year of the forecast. What are the main reasons for this decline and the resurgence? Do any early-stage therapies have the potential to reverse this trend later in the forecast period? If so, where would such therapies fit into the treatment algorithm?<\/p>\n","protected":false},"template":"","class_list":["post-391025","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-unipolar-depression","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391025\/revisions"}],"predecessor-version":[{"id":394148,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391025\/revisions\/394148"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}